Diabetic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Diabetic neuropathy is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning, and pain.

The Diabetic Neuropathy pipeline drugs market research report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report reviews key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects.

Diabetic Neuropathy Pipeline Drugs Market Segmentation by Targets

Some of the key targets of the Diabetic Neuropathy pipeline drugs market are Transient Receptor Potential Cation Channel Subfamily V Member 1, Aldose Reductase, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Heat Shock Protein 90, G Protein Coupled Receptor, Hepatocyte Growth Factor, Interleukin 6 Receptor, Lysophosphatidic Acid Receptor 1, and Mannan Binding Lectin Serine Protease 2.

Diabetic Neuropathy Pipeline Drugs Market Analysis, by Targets

Diabetic Neuropathy Pipeline Drugs Market Analysis, by Targets

For more Diabetic Neuropathy pipeline drugs market target insights, download a free report sample

Diabetic Neuropathy Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Diabetic Neuropathy pipeline drugs market are Aldose Reductase Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Heat Shock Protein 90 Inhibitor, Transient Receptor Potential Cation Channel Subfamily V Member 1 Activator, G Protein Coupled Receptor Agonist, Hepatocyte Growth Factor Activator, Interleukin 6 Receptor Agonist, Lysophosphatidic Acid Receptor 1 Antagonist, and Mannan Binding Lectin Serine Protease 2 Inhibitor.

Diabetic Neuropathy Pipeline Drugs Market Analysis, by Mechanisms of Action

Diabetic Neuropathy Pipeline Drugs Market Analysis, by Mechanisms of Action

For more mechanism of action insights into the Diabetic Neuropathy pipeline drugs market, download a free report sample

Diabetic Neuropathy Pipeline Drugs Market Segmentation by Routes of Administration

Some of the key routes of administration in the Diabetic Neuropathy pipeline drugs market are oral, topical, subcutaneous, intravenous, intramuscular, sublingual, and transdermal.

Diabetic Neuropathy Pipeline Drugs Market Analysis, by Routes of Administration

Diabetic Neuropathy Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Diabetic Neuropathy pipeline drugs market, download a free report sample

Diabetic Neuropathy Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Diabetic Neuropathy pipeline drugs market are small molecule, monoclonal antibody, gene therapy, peptide, protein, and recombinant protein.

Diabetic Neuropathy Pipeline Drugs Market Analysis, by Molecule Types

Diabetic Neuropathy Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Diabetic Neuropathy pipeline drugs market, download a free report sample

Diabetic Neuropathy Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Diabetic Neuropathy pipeline drugs market are Praetego Inc, Glycadia Inc, Korea United Pharm Inc, Medifron DBT Co Ltd, Reata Pharmaceuticals Inc, Releviate Therapeutics, Zhejiang Pharmaceutical Co Ltd, Achelios Therapeutics Inc, Applied Therapeutics Inc, and Beijing Tide Pharmaceutical Co Ltd.

Diabetic Neuropathy Pipeline Drugs Market Analysis, by Companies

Diabetic Neuropathy Pipeline Drugs Market Analysis, by Companies

To know more about the companies in the Diabetic Neuropathy pipeline drugs market, download a free report sample

Diabetic Neuropathy Pipeline Drugs Market Report Overview

Key Targets Transient Receptor Potential Cation Channel Subfamily V Member 1, Aldose Reductase, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Heat Shock Protein 90, G Protein Coupled Receptor, Hepatocyte Growth Factor, Interleukin 6 Receptor, Lysophosphatidic Acid Receptor 1, and Mannan Binding Lectin Serine Protease 2
Key Mechanisms of Action Aldose Reductase Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Heat Shock Protein 90 Inhibitor, Transient Receptor Potential Cation Channel Subfamily V Member 1 Activator, G Protein Coupled Receptor Agonist, Hepatocyte Growth Factor Activator, Interleukin 6 Receptor Agonist, Lysophosphatidic Acid Receptor 1 Antagonist, and Mannan Binding Lectin Serine Protease 2 Inhibitor
Key Routes of Administration Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Sublingual, and Transdermal
Key Molecule Types Small Molecule, Monoclonal Antibody, Gene Therapy, Peptide, Protein, and Recombinant Protein
Leading Companies Praetego Inc, Glycadia Inc, Korea United Pharm Inc, Medifron DBT Co Ltd, Reata Pharmaceuticals Inc, Releviate Therapeutics, Zhejiang Pharmaceutical Co Ltd, Achelios Therapeutics Inc, Applied Therapeutics Inc, and Beijing Tide Pharmaceutical Co Ltd

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
  • Reviews of pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • Evaluation of Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Achelios Therapeutics Inc
Applied Therapeutics Inc
Beijing Tide Pharmaceutical Co Ltd
Bexion Pharmaceuticals LLC
Celon Pharma SA
CSPC Pharmaceutical Group Ltd
Epigen Biosciences Inc
Exodos Life Sciences Limited Partnership
Frontbio Co Ltd
G&P Bioscience Co Ltd
Glycadia Inc
Grunenthal GmbH
Han Wha Pharma Co Ltd
Ion Channel Pharmacology LLC
JanOne Inc
Korea United Pharm Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Omeros Corp
Ono Pharmaceutical Co Ltd
Palisade Bio, Inc
Praetego Inc
Pure Green Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Releviate Therapeutics
Shandong Huizhi Pharmaceutical Technology Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sonnet BioTherapeutics Holdings Inc
WEX Pharmaceuticals Inc
Winsantor Inc
Zelira Therapeutics Ltd
Zhejiang Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Diabetic Neuropathy – Overview

Diabetic Neuropathy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Neuropathy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Neuropathy – Companies Involved in Therapeutics Development

Achelios Therapeutics Inc

Applied Therapeutics Inc

Beijing Tide Pharmaceutical Co Ltd

Bexion Pharmaceuticals LLC

Celon Pharma SA

CSPC Pharmaceutical Group Ltd

Epigen Biosciences Inc

Exodos Life Sciences Limited Partnership

Frontbio Co Ltd

G&P Bioscience Co Ltd

Glycadia Inc

Grunenthal GmbH

Han Wha Pharma Co Ltd

Ion Channel Pharmacology LLC

JanOne Inc

Korea United Pharm Inc

Medifron DBT Co Ltd

Mitsubishi Tanabe Pharma Corp

Omeros Corp

Ono Pharmaceutical Co Ltd

Palisade Bio, Inc

Praetego Inc

Pure Green Pharmaceuticals Inc

Reata Pharmaceuticals Inc

Releviate Therapeutics

Shandong Huizhi Pharmaceutical Technology Co Ltd

Sichuan Haisco Pharmaceutical Co Ltd

Sonnet BioTherapeutics Holdings Inc

WEX Pharmaceuticals Inc

Winsantor Inc

Zelira Therapeutics Ltd

Zhejiang Pharmaceutical Co Ltd

Diabetic Neuropathy – Drug Profiles

A-717 – Drug Profile

Product Description

Mechanism Of Action

atexakin alfa – Drug Profile

Product Description

Mechanism Of Action

BXQ-350 – Drug Profile

Product Description

Mechanism Of Action

caficrestat – Drug Profile

Product Description

Mechanism Of Action

CPL-207280CA – Drug Profile

Product Description

Mechanism Of Action

elismetrep – Drug Profile

Product Description

Mechanism Of Action

EPGN-2154 – Drug Profile

Product Description

Mechanism Of Action

FB-118B1 – Drug Profile

Product Description

Mechanism Of Action

GB-102 – Drug Profile

Product Description

Mechanism Of Action

GLY-230 – Drug Profile

Product Description

Mechanism Of Action

HSK-16149 – Drug Profile

Product Description

Mechanism Of Action

ketoprofen – Drug Profile

Product Description

Mechanism Of Action

KU-32 – Drug Profile

Product Description

Mechanism Of Action

lidocaine – Drug Profile

Product Description

Mechanism Of Action

MDR-16523 – Drug Profile

Product Description

Mechanism Of Action

MDR-652 – Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis – Drug Profile

Product Description

Mechanism Of Action

NSI-189 – Drug Profile

Product Description

Mechanism Of Action

ONO-2910 – Drug Profile

Product Description

Mechanism Of Action

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health – Drug Profile

Product Description

Mechanism Of Action

PGDN-20WS – Drug Profile

Product Description

Mechanism Of Action

pirenzepine – Drug Profile

Product Description

Mechanism Of Action

PTG-6 – Drug Profile

Product Description

Mechanism Of Action

PTG-640 – Drug Profile

Product Description

Mechanism Of Action

PTG-641 – Drug Profile

Product Description

Mechanism Of Action

resiniferatoxin – Drug Profile

Product Description

Mechanism Of Action

RLVT-1402 – Drug Profile

Product Description

Mechanism Of Action

RLVT-903 – Drug Profile

Product Description

Mechanism Of Action

RTA-901 – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Algodystrophy, Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Pain – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Diabetic Peripheral Neuropathy – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Agonize MOR1 for Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Postherpetic Neuralgia – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Agonize CB1 and CB2 for Diabetic Neuropathy and Peripheral Arterial Disease – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Target Plasminogen for Chronic Inflammatory Diseases and Diabetic Neuropathy – Drug Profile

Product Description

Mechanism Of Action

sodium nitrite SR – Drug Profile

Product Description

Mechanism Of Action

SYHA-1402 – Drug Profile

Product Description

Mechanism Of Action

Tetrodotoxin – Drug Profile

Product Description

Mechanism Of Action

UI-016 – Drug Profile

Product Description

Mechanism Of Action

UI-048 – Drug Profile

Product Description

Mechanism Of Action

YJ-001 – Drug Profile

Product Description

Mechanism Of Action

YJC-007 – Drug Profile

Product Description

Mechanism Of Action

Diabetic Neuropathy – Dormant Projects

Diabetic Neuropathy – Discontinued Products

Diabetic Neuropathy – Product Development Milestones

Featured News & Press Releases

Aug 02, 2021: Innovative drug HSK16149 capsule was approved to carry out phase II clinical trial of “auxiliary opioid analgesia”

Jun 02, 2021: Innovative drug HSK16149 capsule new indications obtained IND application “Notice of Acceptance”

May 13, 2021: Pure Green Pharmaceuticals reports unexpected results of a randomized, placebo controlled clinical trial with sublingual CBD in patients with painful diabetic peripheral neuropathy

Apr 01, 2021: Celon Pharma announces CPL’280, second generation oral GPR40 agonist, meets primary endpoint in phase 1 trial

Jan 25, 2021: Sonnet BioTherapeutics announces the successful completion of a non-human primate toxicology study of SON-080

Sep 30, 2020: Praetego receives NIH phase 2 STTR funding to advance novel amadorin drug candidates for diabetic peripheral neuropathy

Apr 12, 2019: “SYHA1402” for the treatment of diabetic neuropathy was granted clinical trial approval

Jun 01, 2018: Reata Selected to Present on its Early-Stage Program RTA 901 at the BIO International Convention

Mar 16, 2018: Reata to Present on its Diabetic Neuropathy Drug Candidate RTA-901 at the BIO Asia International Conference

Aug 02, 2017: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy

Sep 04, 2016: Salvianolic acid A tablets developed by the National Drug Screening Center received clinical approval

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Diabetic Neuropathy, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Diabetic Neuropathy – Dormant Projects, 2022

Diabetic Neuropathy – Dormant Projects, 2022 (Contd..1)

Diabetic Neuropathy – Dormant Projects, 2022 (Contd..2)

Diabetic Neuropathy – Dormant Projects, 2022 (Contd..3)

Diabetic Neuropathy – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Diabetic Neuropathy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Diabetic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Diabetic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Diabetic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Diabetic Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.